Celltrion acquires Australian approval of trastuzumab biosimilar ‘Herzuma’

Celltrion recently announced they acquired sales approval of therapeutic antibody biosimilar for breast cancer and stomach cancer ‘Herzuma(generic name: trastuzumab)’ from the Australian Therapeutic Goods Administration.

‘Herzuma,’ the only trastuzumab biosimilar which acquired the approval in Australia, is a biosimilar of antibody for the treatment early breast cancer, locally advanced breast...